Bharat Biotech, Washington University to make nasal vaccine |
Clinical News
eMediNexus Coverage from: 
Bharat Biotech, Washington University to make nasal vaccine

2 Read Comments                

Hyderabad: Bharat Biotech has entered into a licensing agreement with the Washington University School of Medicine in St Louis (WashU) for developing, conducting clinical trials, manufacturing and distributing a chimp-adenovirus, single dose intranasal vaccine candidate for COVID-19.

According to the deal, Bharat Biotech will distribute the vaccine in all global markets, excluding US, Europe and Japan. The Phase I trials for the vaccine will be conducted in Saint Louis University’s vaccine and treatment evaluation unit.The company will look after further clinical trials for the vaccine in India following approvals. Large scale manufacturing of the vaccine will be carried out at the company’s facility in Hyderabad. It plans to manufacture about a billion doses… (ET Healthworld – TNN, September 24, 2020)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now